Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib

di Johnson, Ted W., Gallego, Rebecca A., Brooun, Alexei, Gehlhaar, Dan, McTigue, Michele
Pubblicato in ACS Med Chem Lett (2018)

Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase

di Johnson, Ted W., Bolanos, Ben, Brooun, Alexei, Gallego, Rebecca A., Gehlhaar, Dan, Jalaie, Mehran, McTigue, Michele, Timofeevski, Sergei
Pubblicato in ACS Med Chem Lett (2018)

The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase

di Gajiwala, Ketan S., Grodsky, Neil, Bolaños, Ben, Feng, Junli, Ferre, RoseAnn, Timofeevski, Sergei, Xu, Meirong, Murray, Brion W., Johnson, Ted W., Stewart, Al
Pubblicato in J Biol Chem (2017)

Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation

di Johnson, Eric, McTigue, Michele, Gallego, Rebecca A., Johnson, Ted W., Timofeevski, Sergei, Maestre, Michael, Fisher, Timothy S., Kania, Robert, Sawasdikosol, Sansana, Burakoff, Steven, Cronin, Ciarán N.
Pubblicato in J Biol Chem (2019)

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

di Cheng, Hengmiao, Li, Chunze, Bailey, Simon, Baxi, Sangita M., Goulet, Lance, Guo, Lisa, Hoffman, Jacqui, Jiang, Ying, Johnson, Theodore Otto, Johnson, Ted W., Knighton, Daniel R., Li, John, Liu, Kevin K.-C., Liu, Zhengyu, Marx, Matthew A., Walls, Marlena, Wells, Peter A., Yin, Min-Jean, Zhu, Jinjiang, Zientek, Michael
Pubblicazione 2012

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

di Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, Fantin, Valeria R.
Pubblicato in Proc Natl Acad Sci U S A (2015)

CNS Anticancer Drug Discovery and Development Conference White Paper

di Levin, Victor A., Tonge, Peter J., Gallo, James M., Birtwistle, Marc R., Dar, Arvin C., Iavarone, Antonio, Paddison, Patrick J., Heffron, Timothy P., Elmquist, William F., Lachowicz, Jean E., Johnson, Ted W., White, Forest M., Sul, Joohee, Smith, Quentin R., Shen, Wang, Sarkaria, Jann N., Samala, Ramakrishna, Wen, Patrick Y., Berry, Donald A., Petter, Russell C.
Pubblicato in Neuro Oncol (2015)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

di Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Pubblicato in N Engl J Med (2015)

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

di Yoda, Satoshi, Lin, Jessica J., Lawrence, Michael S., Burke, Benjamin J., Friboulet, Luc, Langenbucher, Adam, Dardaei, Leila, Prutisto-Chang, Kylie, Dagogo-Jack, Ibiayi, Timofeevski, Sergei, Hubbeling, Harper, Gainor, Justin F., Ferris, Lorin A., Riley, Amanda K., Kattermann, Krystina E., Timonina, Daria, Heist, Rebecca S., Iafrate, A. John, Benes, Cyril H., Lennerz, Jochen K., Mino-Kenudson, Mari, Engelman, Jeffrey A., Johnson, Ted W., Hata, Aaron N., Shaw, Alice T.
Pubblicato in Cancer Discov (2018)

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer

di Lin, Jessica J., Choudhury, Noura J., Yoda, Satoshi, Zhu, Viola W., Johnson, Ted W., Sakhtemani, Ramin, Dagogo-Jack, Ibiayi, Digumarthy, Subba R., Lee, Charlotte, Do, Andrew, Peterson, Jennifer, Prutisto-Chang, Kylie, Malik, Wafa, Hubbeling, Harper G., Langenbucher, Adam, Schoenfeld, Adam J., Falcon, Christina J., Temel, Jennifer S., Sequist, Lecia V., Yeap, Beow Y., Lennerz, Jochen K., Shaw, Alice T., Lawrence, Michael S., Ou, Sai-Hong Ignatius, Hata, Aaron N., Drilon, Alexander, Gainor, Justin F.
Pubblicato in Clin Cancer Res (2021)

PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1(st) and 2(nd) generation ALK inhibitors in pre-clinical models

di Zou, Helen Y., Friboulet, Luc, Kodack, David P., Engstrom, Lars D., Li, Qiuhua, West, Melissa, Tang, Ruth W., Wang, Hui, Tsaparikos, Konstantinos, Wang, Jinwei, Timofeevski, Sergei, Katayama, Ryohei, Dinh, Dac M., Lam, Hieu, Lam, Justine L., Yamazaki, Shinji, Hu, Wenyue, Patel, Bhushankumar, Bezwada, Divya, Frias, Rosa L., Lifshits, Eugene, Mahmood, Sidra, Gainor, Justin F., Affolter, Timothy, Lappin, Patrick B., Gukasyan, Hovhannes, Lee, Nathan, Deng, Shibing, Jain, Rakesh K, Johnson, Ted W., Shaw, Alice T., Fantin, Valeria R., Smeal, Tod
Pubblicato in Cancer Cell (2015)